SiteOne Therapeutics, in Bozeman, MT, was founded on technology invented at Stanford Univ. that represents a revolutionary advancement in the treatment of acute and chronic pain. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors. Given the critical role Naᵥ1.7 plays in generating pain signals, and the need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead product for the treatment of moderate to severe pain.
Location: United States, Montana, Bozeman
Employees: 11-50
Total raised: $101.73M
Founded date: 2010
Investors 4
| Date | Name | Website |
| - | Next Front... | nextfronti... |
| - | Mission Bi... | missionbio... |
| - | Biobrit | biobrit.co... |
| - | MBC BioLab... | mbcbiolabs... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.12.2024 | Series C | $100M | - |
| 11.05.2021 | Grant | $1.73M | - |
Mentions in press and media 12
| Date | Title | Description |
| 05.02.2025 | Funding Is Flush For Startups Focused On Treating Pain | 3 Shares Email Facebook Twitter LinkedIn Big pharma and startups alike have put huge efforts over the years into finding effective and nonaddictive treatments for pain. For the most part, it’s been a slow-going slog. Last week, however, the... |
| 24.12.2024 | SiteOne Therapeutics: A New Dawn in Non-Opioid Pain Management | In a world where pain management often leads to addiction, SiteOne Therapeutics is carving a new path. The San Francisco-based biotech has just secured $100 million in Series C funding, led by Novo Holdings. This investment marks a signific... |
| 24.12.2024 | SiteOne Therapeutics: $100 Million (Series C) Raised For Advancing Selective Ion Channel Modulators For Pain Management | SiteOne Therapeutics – a biopharmaceutical company developing selective ion channel modulators for treating pain, cough, and other conditions – announced a $100 million Series C financing. Led by Novo Holdings, with participation from OrbiM... |
| 18.12.2024 | Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments | SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral nervous system instead of the central nervous system. The biotech’s series C financing was led by Novo... |
| 18.12.2024 | SiteOne Therapeutics Raises $100M in Series C Financing | SiteOne Therapeutics, a San Francisco, CA-based biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, raised $100M in Series C funding. The round was led by Novo Holdin... |
| 11.05.2021 | SiteOne Therapeutics Announces $1.73M Grant from NIH/NHLBI and Adds Respiratory Advisory Team | |
| 11.05.2021 | SiteOne Therapeutics : Announces $1.73M Grant from NIH/NHLBI and Adds Respiratory Advisory Team | SOUTH SAN FRANCISCO, Calif., May 11, 2021 /PRNewswire/ -- SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announc... |
| 20.04.2021 | SiteOne Therapeutics Announces Initiation of Phase 1 Clinical Trial for its Non-Opioid Analgesic for Acute Pain | |
| 09.01.2017 | SiteOne Therapeutics Bags $15M Series B | BOZEMAN, MT, SiteOne announced the formal closing of a $15 million series B round of financing, led by Amgen. >> Click here for more funding data on SiteOne Therapeutics >> To export SiteOne Therapeutics funding data to PDF ... |
| 09.01.2017 | Amgen Leads Investment In SiteOne Therapeutics | Thousand Oaks-based Amgen is the lead investor in a round for San Francisco- and Bozeman, Montana-based SiteOne Therapeutics, SiteOne said on Friday. SiteOne said it raised $15M in a Series B funding round, which was led b Amgen, and also i... |
Show more